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Abstract
Background: Unnecessary use of anti-infectives for systemic use is a major global issue and often results in too many problems such as: ineffective 
treatment and side effects in patients, increase of  the risk of development of pathogen microbial resistance and treatment costs. Defined daily doses 
(DDD) is a method that integrated the evaluation of drugs consumption of worldwide hospitals, giving the possibility of comparison, improving the 
rational use, optimizing the possibility of coherent planning of antibiotics necessities.
Material and methods: The data of this study represents a six-year (2009-2014) period in Reanimation Department, which describes the consumption 
dynamics of anti-infectives for systemic use of drugs in natural and value indexes. 
Results: The defined daily doses (DDD) per 1000 occupied-bed days (DDD/1000) of antibiotics in Reanimation Department has decreased from 3270.17 
in 2009 to 1664.99 in 2014 and is by 22.76% higher than medium consumption of 1286.11 DDD/1000 in 1134 intensive care units from international 
hospitals. The value indexes per DDD/1000 declined from 87860 in 2009 to 54307 lei in 2014 or by 38.19%, when the cost of one medium DDD increased 
from 26.87 in 2009 to 32.62 lei or by 21.40% in 2014. The pharmacoeconomy from 2010 to 2014 increased more than by 3 times. 
Conclusions: The stated decrease in DDD/1000 OBD and the obtained pharmacoeconomy characterized the measures taken to improve the rational use 
of antibiotics.  The increase of one DDD cost, shows the increase in the price of antibiotic medical remedies for the evaluated period. 
Key words: antibiotics, defined daily dose, consumption, rational use, hospitals, occupied-bed days, indices.
Introduction
The unnecessary use of antibiotics is a major global issue 
and often results in a great deal of problems, such as: ineffec-
tive treatment and side effects in patients, increased risk of 
development and dissemination of pathogen microbes resis-
tance, triggered super infections and the increased treatment 
costs [1-6]. The data about morbidity and mortality, as well as 
unnecessary or inappropriate consumption of antibiotics in 
acute care hospitals of The United States, caused Centers for 
Disease Control and Prevention to recommend all acute care 
hospitals to implement Antibiotic Stewardship Programs [7].
It is known that in the Republic of Moldova drugs con-
sumption analysis in defined daily doses (DDD) per 1000 
occupied-bed days (DDD/1000), is an important objective 
indicator of drugs consumption evaluation, the result of which 
is serving as real database for optimizing the rational use and 
planning the medical necessities in health care institutions. 
This issue is not taken seriously enough and highlighted in 
the national scientific research literature. 
The primary aim of this study is directed to determine the 
value of DDD/1000 in accordance with World Health Orga-
nization (WHO) requirements [8, 9] based on the evaluation 
of antibiotics consumption of the institutional representative 
data in Reanimation department for a six-year period (2009-
2014). The obtained results from Reanimation department, 
in comparison with the published ones in intensive care units 
from worldwide hospitals, will permit to recommend measu-
res to ensure the rational use and optimization of planning the 
annual necessities of anti-infectives for systemic use.
The Emergency Medicine Institute of the Republic of Mol-
dova (EMI) was founded in 1959.  The clinical services of EMI 
include: Orthopedic-Traumatology for 150 beds, Surgery for 
140 beds, Neurosurgery for 80 beds, Neurology for 70 beds, 
Maxillofacial for 30 beds, Urology for 40 beds, Gynecology 
for 30 beds, Microsurgery for 30 beds, Municipal center for 
hemodialysis with 8 seats and 9 beds, Clinical Intensive Care 
Unit for 30 beds and Reanimation department for 23 beds. The 
above-mentioned clinical services include 600 beds overall. In 
addition to the above-mentioned services, there are 4 more ou-
tpatient Departments of traumatology and orthopedics [10].
Material and methods
The study uses data of a six-year period (2009-2014), 
from EMI Reanimation Department for 23 beds that shows 
the dynamics of consumption of anti-infectives for systemic 
use, in accordance with Anatomical Therapeutic Chemical 
(ATC) classifications system of World Health Organization, 
indicated in natural and value indexes. Statistical, analytical, 
mathematical, comparative, logical and descriptive methods 
were used in the study.
Results and discussion
To evaluate the consumption of anti-infectives for systemic 
use, were taken 10 steps necessary to determine the DDD/1000 
[11], the statistics data concerning the number of treated pati-
ents (only patients with health insurance and other free treated 
by the state categories of citizens) and occupied bed-days/per 
year:  (2009 = 3990; 2010 = 6551; 2011 = 6985; 2012 = 9051; 
2013 = 7384;  2014 = 7361), as well as the data related to the 
total annual consumption of antibiotics were used. 
All in all, 50 antimicrobial remedies (both for parenteral 
and enteral use) for hospitalized patients’ treatment in the 
evaluated period were used: 12 enteral forms; 18 parenteral 
forms and 10 names of both forms, which represent 40 active 
antimicrobial substances.
Rate of antibiotics subgroups consumption of parenteral 
forms evaluated in DDD/1000 during  2009-2014 period is 
shown in figure 1.
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In figure 1 is demonstrated the average consumption 
annual rate of parenteral forms for the evaluated period for 
all antibiotic subgroups that recorded a decline from 3172 
in 2009 to 1629 DDD/1000 in 2014 or by 48.64%. The main 
consumption of 2369.42 DDD/1000 or 74.70% from the total 
in 2009 to 1244.67 or 76.41% from the total in 2014, shows 
a decrease from the mentioned period of 47.47% for other 
beta-lactam antibacterials (Cefazolinum 3.0, Cefuroximum 
3.0, Cefotaximum 4.0, Ceftazidimum 4.0, Ceftriaxonum 2.0, 
Cefoperazonum 4.0), aminoglycoside antibacterials (Strep-
tomycinum 1.0, Gentamycinum 0.2, Kanamycinum 1.0, 
Amikacinum 1.0) and other antibacterials (Vancomycinum 
2.0, Metronidazolum1.5, Dioxydinum 0.7, Nitroxolinum 1.0). 
The mean consumption with a decrease in the mentioned 
period by 52.16%, from 770.43 DDD/1000 or 24.29% of the 
total in 2009 to 368.56 or 22.63% of the total in 2014 was re-
corded by beta-lactam antibacterials, penicillins, quinolone 
antibacterials and antimycotics for systemic use. Macrolides, 
lincosamides and streptogramins (Clarithromycinum 0.5, 
Azithromycinum 0.5, Lincomycinum 1.8) and amphenicols 
(Chloramphenicolum 0.3) showed a decline in consumption 
by 51.50%, from 32.08 DDD/1000 or 1.01% of the total in 
2009 to 15.56 or 0.96% of the total in 2014, and were placed 
on the last third position. 
In figure 2 is shown the consumption rate of enteral forms 
of antibacterials for systemic use subgroups in DDD/1000, 
during 2009-2014.
Figure 2 shows the average consumption annual rate of an-
tibiotics for oral use that recorded an instable rate and is more 
appropriate to 80-100 DDD/1000 during four years: 2009, 
2011, 2012 and 2013. The consumption of 80.45 DDD/1000 
or 81.88% of the total in 2009 to 33.28 or 92.45% of the total 
in 2014 was registered by the antimycotics for systemic use 
(Ketoconazolum 0.2, Fluconazolum 0.2), they showed a de-
crease by 58.63%, when other subgroups registered only an 
episodic consumption for the same period. Figure 3 shows 
the total (parenteral and enteral forms) antibiotic subgroups 
usage rates.
Figure 3 states the average consumption annual rate of pa-
renteral and enteral forms for all antibiotic subgroups that re-
corded a decline from 3270 in 2009 to 1665 DDD/1000 in 2014 
or by 49.08%. The main consumption of 2369.42 DDD/1000 
or 72.46% of the total in 2009 to 1244.67 or 74.76% of the 
total in 2014 with a decrease of 47.47% during the evaluated 
period, was registered for other beta-lactam antibacterials, 
Table 1
The ratio between DDD/1000 for parenteral to enteral antibiotics forms
Years 2009 2 010 2011 2012 2013 2014
Parenteral 3171.9 1739.4 1583.5 1609 1706.4 1629
Enteral 98.25 43.51 79.36 83.31 107.67 36
The ratio of parenteral to oral 32.28 39.98 19.95 19.31 15.85 45.25
Total 3270.5 1782.1 1662.6 1692.1 1814.7 1665
Percentage forms from 
total
Parenteral 97.56 95.23 95.08 94.06 97.84 97.84
Enteral 2.44 4.77 4.92 5.94 2.16 2.16
Fig. 1.  Parenteral consumption forms of antibacterials for 
systemic use in DDD/1000.
Fig. 2.  Enteral consumption forms of antibacterials  
for systemic use in DDD/1000.
Fig. 3.  The total consumption of antibacterials  
for systemic use in DDD/1000.
aminoglycoside antibacterials and other antibacterial. The 
mean consumption with a decrease by 53.55% from 865.17 
DDD/1000 or 26.46% of the total in 2009 to 401.84 or 24.14% 
of the total in 2014 was recorded by beta-lactam antibacteri-
als, penicillins, quinolone antibacterials and antimycotics for 
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systemic use. Macrolides, lincosamides and streptogramins 
(Clarithromycinum 0.5, Azithromycinum 0.5, Lincomycinum 
1.8) and amphenicols (Chloramphenicolum 0.3) were placed 
on the last position with a decline of 51.90% consumption 
from 35.59 DDD/1000 or 1.09% of the total in 2009 to 17.12 
or 1.03% of the total in 2014. Table 1 demonstrates the ratio 
DDD/1000 of parenteral to enteral use forms and percentage 
from the total.
As stated in table 1 for the evaluated period, the ratio 
between antibiotics DDD/1000 parenteral to enteral forms 
recorded an instable report between 15 and 20 times du-
ring  three years (2011-2013), as well as from 30 to 45 times 
during other three years (2009-2010; 2014). From the total 
DDD/1000, the percentage of parenteral forms of antibiotics, 
was more or less the same in the mentioned period with the 
annual average of 96%, as well as the enteral forms from 2% 
to 6%. Similar data of DDD/1000 for the entire institution can 
be found in recent publications [12]. 
The comparison of total consumption data of the an-
ti-infectives for systemic use, evaluated in DDD in 1576 
international hospitals and their intensive care units with 
the similar data in the EMI and Reanimation department, is 
presented in table 2. 
Table 2 states the average annual rate for total-hospital an-
tibiotics utilization period in EMI that decreased from 662.4 in 
2009 to 464.1 DDD/1000 in 2014 or by 30%. The overall medium 
consumption in 1706 international hospitals, constituting 459.20 
DDD/1000, was lower than the consumption of 464.1 DDD/1000 
in EMI in 2014 by 4.90 DDD/1000, and, lower by 121.1 compara-
tively to medium global annual hospital antibiotics consumption 
of 343 DDD/1000 or by 20.09% [13].
The Reanimation department registered a decrease of 
antibiotics consumption  from 3270.17 in 2009 to 1664.99 
DDD/1000 in 2014 or by 49.09% respectively. An approximate 
calculation of DDD/1000 was conducted for 1134 intensive 
care units of international hospitals that resulted in an average 
consumption of 1286.11 DDD/1000{[(10x1013.1 + 2x1762.3 
+ 1x982 + 38x1016 + 38x1143 + 35x1254 + 1x1761 + 1x683 
+ 43x1156 + 34x1110 + 58x1400 + 38x1335 + 8x1223 + 
744x1332 + 1x1260 + 40x1169 + 40x1127 + 1x1109 + 1x1052) 
= 1458445 : 1134] = 1286.11DDD/1000}, which was 1984.06 
in 2009 or by 60.67% and 378.88 DDD/1000 in 2014 or by 
Table 2
Surveillance studies of antibiotics use in international hospitals, comparing with the similar data 
in Emergency Medicine Institute and Reanimation department 
Setting Surveillance  time-period Data source
Frequency of 
data collection
Use of antibiotics 
 in DDD/1000




Annual 662.4 in 2009;                  464.1 in 2014.
Reanimation departmnent of EMI 6 years (2009–2014) (PDR) Annual 3270.17 in 2009;               1664.99 in 2014.
10 primary and 2 secondary acute care hospitals in the Can-
ton of Zurich in Switzerland [14] in 2006 (PDR) Annual 1013.1 to 1762.3
1 university hospital in Greece [15] 5 years (1998-2002) (PDR) Annual 982.0
54% of the national acute care hospitals in Switzerland [16] 5 years  (2004- 2008) (PDR) Annual 1016.0 to 1143.0
38 ICUs providing services to a population of approximately 
6 million in Sweden [17] in  1999 (PDR) Annual 1257.0
35 European Intensive Care Units [18] in2005 (PDR) Annual 1254.0
Spanish general hospital [19] 5 years  (1996–2000) (PDR) Annual 1761.6
Geneva University Hospital and its adult ICUs [20] 5 years  (1996–2000) (PDR) Annual 683.0
43 intensive care units in Germany [21] in  2005 (PDR) Annual 1156.0
2 cohorts of intensive care units (ICUs) in Germany (N=34), 
(N=58) [22] in the  2005 (PDR) Annual 1110.0 and  1400.0
38 German  general, surgical, and  interdisciplinary ICUs in 
[23] 4 years  (2000- 2003) (PDR) Annual 1335.0
8 German University Hospitals [24] 3 years  (1998-2000) (PDR) Annual 1223.0
744 reported ICU in Germany [25] 3 years  (2000-2002) (PDR) Annual 1332.0
The main university clinic for medical emergencies from 
Bucharest municipality[26] in  2008 (PDR) Annual 1260.0
40 non–university regional general hospitals in southwestern 
Germany [27] 2 years (2001- 2002) (PDR) Annual 1169.0 and 112.7
Military Medical Academy hospital of Bulgaria [28] in 2011 (PDR) Annual 1109.0 and 1052.0
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22.76% that was more than the results recorded in Reanima-
tion department of EMI. In figure 4 the total consumption 
of other beta-lactam antibacterials for parenteral and enteral 
use in DDD/1000 is demonstrated.
The chart states a registration of a total stable consumption 
of parenteral forms during the years of 2010, 2011, 2012 and 
2014 from 763 to 887 DDD/1000, which is more characteristic 
for all the evaluated period, with high records of 1417 in 2009 
and 1032 DDD/1000 in 2013. The cephalosporin’s G-I (Cefa-
lexinum and Cefazolinum) consumption has visibly decreased 
from 525.06 DDD/1000 in 2009 to 116.56 in 2014 or by 77.8%. 
The cephalosporin’s G-II (Cefuroximum, Cefaclorum) and 
G-III (Cefotaximum, Ceftazidimum, Ceftriaxonum, Cefixim, 
Cefoperazonum, Cefoperazonum +  Sulbactamum) consump-
tions show a slow decrease from 880.2 (70.68+809.52) in 2009 
to 730.20 DDD/1000 (127.56+602.64) or by 17.04%. The 
carbapemens (Meropenemum, Imipenemum+Cilastatinum) 
recorded an increment from 11.28 DDD/1000 in 2010 to 39.94 
in 2011 that was by 3.54 times more. The cephalosporins G-IV 
registered the only consumption in 2011. Figure 5 shows the 
value cost of DDD/1000 in lei for parenteral forms of anti-
bacterials for systemic use during 2009 - 2014.
Figure 5 demonstrates that the cost of DDD/1000 in value 
indexes (lei) of subgroups with antibiotics for parenteral use, 
recorded a decline from 86856 in 2009 to 54204 lei in 2014 or 
by 37.59%. The increment in cost per DDD/1000 of 2146.52 
from 11865.96 lei (6246.62 + 5587.22 + 32.12) in 2009 to 
14012.48 lei (8041.70 + 5879.70 + 91.08) in 2014 or by 18.09% 
was recorded by 3 subgroups: beta-lactam antibacterials, 
penicillins, aminoglycoside antibacterials and amphenicols. 
The following subgroups: other  beta-lactam antibacterials, 
quinolone antibacterials,  antimycotics for systemic use, other 
antibacterials, macrolides, lincosamides and streptogra-
mins recorded a decline of cost per DDD/1000 from 74990 
(40122.89 + 19035.30 + 8977.57 + 5826.32 + 1027.92) in 2009 
to 40191 lei (33981.3 + 3366.60 + 458.56 + 1793.70 + 591.22) 
in 2014 or by 46.41%. Figure 6 shows the consumption rate in 
value indexes in lei, for subgroups with antibiotics for enteral 
forms per DDD/1000, during 2009-2014.
Figure 6 shows an unstable amount of lei spent per 
DDD/1000 during 2009 to 2014, recording the highest in 
2009 and abrupt decline in 2014, that amounted to 103 lei per 
DDD/1000 or by 9.70 times. The main annual consumption 
rate per DDD/1000 in value indexes of all antibiotic subgroups 
recorded antimicotics for systemic use with a decline from 
866.05 or 86.29% of the total in 2009 to 98.42 lei or 95.71% 
of the total in 2014 or by 8.80 times. 
The total institutional antibiotics consumption in value 
indexes varied from 1562575 in 2009 to 1500888 lei in 2014, 
which represents respectively 17% and 14% from whole 
amount of drugs [29]. The same data for Reanimation depart-
ment was 341581 in 2009 and 399754 lei in 2014 or 22.34% 
and 20.03% respectively from the whole amount of drugs, and 
21.88% and 26.63% from the total institutional antibiotics 
consumption. Figure 7 states the consumption rate in value 
indexes (lei) of subgroups with antibiotics for parenteral and 
enteral forms in DDD/1000 during 2009-2014.
Fig. 4.  Total consumption of other beta-lactam antibacterials for 
parenteral use in DDD/1000.
Fig. 5.  Value cost of parenteral forms of antibacterials for 
systemic use per DDD/1000 in lei.
Fig. 6.  Value cost for enteral forms of antibacterials for systemic 
use per DDD/1000 in lei.
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In chart 7 the presented data demonstrates that in the 
evaluated period total annual antibiotics consumption in 
value indexes per DDD/1000, recorded a decline from 87860 
in 2009 to 54307 lei in 2014 or by 38.19%. In figure 8 is pre-
sented the total value cost of other beta-lactam antibacterials 
for parenteral use of DDD/1000 in lei.
Fig. 8.  Total value cost of other beta-lactam antibacterials for 
parenteral use of DDD/1000  in lei.
Figure 5 shows that the cost of DDD/1000 in value indexes 
(lei) of subgroups with antibiotics for parenteral use recorded a 
decline from 40128 in 2009 to 33981 lei in 2014 or by 15.32%. 
An exceptional decline was in 2013 year with the higher 
consumption of 42799 lei per DDD/1000. The increment in 
cost per DDD/1000 was recorded by the second generation 
of cephalosporin from 3481.95 in 2009 to 4528.20 lei in 2014 
or by 30.05%. First and third cephalosporin generations and 
carbapenems, recorded a decline from 36646.19 (5856.39 
+ 21224.8 + 9565) in 2009 to 29453.10 lei (1124.1 + 20913 
+7416) in 2014 or by 19.63%.
To determine the cost of one medium DDD of antibac-
terials for systemic use separately for parenteral and enteral 
forms, the value cost of DDD/1000 to DDD/1000 was divided 
respectively. The medium cost of one antibiotic DDD in lei 
for parenteral and enteral forms is shown in tables 3 and 4 
Table 3 states that in the evaluated period the total cost of 
one medium DDD increased from 26.87 in 2009 to 32.62 lei 
in 2014 or by 21.40% and of parenteral forms from 27.38 to 
33.27 lei or by 21.51%. For enteral forms this cost registered a 
significant decrease from 10.22 to 2.86 lei or by 3.57 times. The 
ratio between the cost of one medium DDD of parenteral and 
enteral forms was respectively 2.68:1; 9.96:1; 12.14:1; 7.01:1; 
9.09:1 and 11.63:1 for the evaluated years.
The calculation of one medium DDD costs in lei of pa-
renteral forms of other beta-lactam antibacterials is shown 
in table 4. As stated in the table for the evaluated period, the 
cost of one medium DDD of parenteral forms increased from 
12.65 to 20.86 lei or by 35.10%. 
The periodical evaluation and presentations of antibiotic 
consumption in DDD led to making practical decisions on 
rational use of this group of drugs. In table 5 are presented the 
results of pharmacoeconomy in the Reanimation Department 
of intensive care.
As stated in table 5, starting from 2009 and taking into 
consideration the exchange rate, the pharmacoeconomy incre-
ased from 14046 in 2010 to 45407 lei in 2014 per DDD/1000 
that amounted to 3.32 times, corresponding to the annual 
savings from 92015,3 to 334241 lei. In case of not taking into 
Table 3
Cost of 1 (one) DDD antibiotics in lei for parenteral and enteral forms 
Reanimation department intensive care unite
  2009 2010 2011 2012 2013 2014
Parenteral cost  in lei DDD/1000 86856 88888.10 78432.60 57993.60 76022.00 54204.00
Enteral cost in lei DDD/1000 1003.66 223.05 323.93 428.13 527.47 102.83
Parenteral and enteral cost of DDD/1000 in lei 87859.66 89111.15 78756.53 58421.73 76549.47 54306.83
Parenteral DDD/1000 3171.90 1739.40 1583.50 1609.00 1706.40 1629.00
Enteral DDD/1000 98.25 43.51 79.36 83.31 107.67 36.00
Parenteral and enteral DDD/1000 3270.15 1782.91 1662.86 1692.31 1814.07 1665.00
Total cost of one  DDD in lei 26.87 49.98 47.36 34.52 42.20 32.62
Parenteral cost of one  DDD in lei 27.38 51.10 49.53 36.04 44.55 33.27
Enteral cost of one  DDD in lei 10.22 5.13 4.08 5.14 4.90 2.86
Table 4
Cost of one DDD other beta-lactam antibacterials in lei of parenteral and enteral forms 
Reanimation department 
  2009 2010 2011 2012 2013 2014
Parenteral cost in lei DDD/1000 40122.89 25566.49 27043.07 23869.4 42798.9 33981.3
Parenteral DDD/1000 3171.90 1739.40 1583.50 1609.00 1706.40 1629.00
Parenteral cost of one DDD in lei 12.65 14.70 17.08 14.84 25.08 20.86
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consideration the exchange rate, the amount was from 63585.2 
to 246981 lei.
Conclusions
1. The DDD/1000 OBD of antibiotics in Reanimation 
department decreased by 49.09% or from 3270.17 in 2009 to 
1664.99 in 2014 and was by 22.76% higher than the medium 
consumption of 1286.11 in 1134 intensive care units of inter-
national hospitals. 
2. The value indexes per DDD/1000 declined from 87860 
in 2009 to 54307 lei in 2014 or by 38.19%. The cost of one 
medium DDD increased from 26.87 in 2009 to 32.62 lei in 
2014 or by 21.40%. The pharmacoeconomy increased yearly 
and in 2014 was more than 3 times, comparatively with 2009. 
3. The average annual institutional rate for the total an-
tibiotics consumption for the stated period decreased from 
662.4 in 2009 to 464.1 DDD/1000 OBD in 2014 or by 30%. The 
overall medium consumption in 1547 international hospitals 
constituting 425.81 DDD/1000 was less than 38.29 DDD/1000 
or by 8.25% than the consumption in 2014 in EMI.
4. The parenteral use forms recorded a decline from 3172 
in 2009 to 1629 DDD/1000 in 2014 or by 48.64% and with 
an unstable consumption for the ones with enteral use forms, 
varying from 38 to 108 DDD/1000 in different years.
5. The total institutional antibiotics consumption in value 
indexes varied from 1562575 in 2009 to 1500888 lei in 2014 
that represents 17% and 14% from the whole amount of drugs. 
The same data for Reanimation department was 341581 in 
2009 and 399754 lei in 2014 or 22.34% and 20.03% from the 
whole amount of drugs, and 21.88% and 26.63% from the 
total institutional antibiotics consumption.
6. The cost of DDD/1000 declined from 87860 in 2009 
to 54307 lei in 2014 or by 38.19%, and vice versa the cost of 
one medium DDD increased from 26.87 in 2009 to 32.62 lei 
in 2014 or by 21.40%, when the cost of one medium DDD of 
parenteral forms of other beta-lactam antibacterials increased 
from 12.65 to 20.86 lei or by 35.10%.
7. The ratio between costs of one medium DDD of paren-
teral and enteral forms were respectively 2.68:1; 9.96:1; 12.14:1; 
7.01:1; 9.09:1 and 11.63:1 for the years under consideration.
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